Abstract
Objective: To study and compare the clinical effects of the combination of different interventional embolization chemotherapy and radiofrequency ablation in patients with primary liver cancer. Methods: In this paper, based on the target data validation of those 60 patients with primary liver cancer treated in the hospital during the period from May 2017 to May 2018, the double-blind method was used for the comparison between groups. Patients in the reference group were treated with the combination of cis-platinum interventional chemoembolization regimen and radiofrequency ablation, while those in the experimental group were treated with the combination of lobaplatin interventional chemoembolization regimen and radiofrequency ablation. Then, the efficacy of both groups was compared. Results: After the treatment, the clinically effective total value, the calculation value of adverse reactions, and the value of IgA, IgM, IgG and AFP of the experimental group were compared with those of the reference group. In addition, the value of IgA, IgM, IgG and AFP of both groups after and before the treatment were compared. The experimental results showed that the data was statistically significant (P<0.05). Conclusion: The combination of lobaplatin and cisplatin interventional embolization chemotherapy and radiofrequency ablation has some effects in patients with primary liver cancer, but the former one showed more significant effects.